early 1990s, which predates many recent advances in medical and interventional therapies. 4 -7 As a result, differences in processes of care and outcomes for AMI patients in the United States and Canada remain incompletely understood. Implicit in these cross-country comparisons is the assumption that the observed differences in processes of care are driven by organizational differences between the 2 health care systems. None of these national comparison studies have considered whether local regional variations in AMI treatment patterns may play a role, however. Indeed, evidence has demonstrated tremendous regional variation in the utilization of medical therapy and cardiac invasive procedures within the United States. [13] [14] [15] [16] [17] Therefore, it is possible that the discrepancy in cardiac procedure rates between the United States and Canada may reflect regional differences in practice patterns rather than national differences in the respective healthcare delivery systems.
Our first objective was to compare contemporary AMI treatment patterns and outcomes between the United States and Canada with clinically abstracted data from cohorts that are representative of routine clinical practice. Furthermore, we aimed to explore whether differences in AMI treatment between the United States and Canada were consistent across each US region.
Methods

National Heart Care Project
The National Heart Care Project is an initiative of the Centers for Medicare and Medicaid Services designed to improve the quality of care for Medicare beneficiaries hospitalized with AMI in the United States. 18 
Enhanced Feedback for Effective Cardiac Treatment Project
The Enhanced Feedback for Effective Cardiac Treatment (EFFECT) project is an ongoing initiative to improve the care of cardiovascular patients in Ontario, Canada. 20, 21 Patients hospitalized with a most responsible diagnosis of AMI from April 1, 1999, to March 31, 2001 , were identified randomly from each of the 103 participating hospitals with the Canadian Institute for Health Information hospital discharge database (International Classification of Diseases, 9th Revision, Clinical Modification, code 410). A "most responsible diagnosis" is the condition most responsible for the length of a patient's hospital stay. This term has been demonstrated to be essentially equivalent for AMI patients to "principal diagnosis," commonly used in the United States to describe the discharge diagnosis responsible for the hospital admission. 4
Study Sample
Because the data sets in the United States and Ontario were constructed independently, we restricted both AMI cohorts in an identical fashion to ensure comparability. We excluded patients who were Ͻ65 years or Ͼ105 years of age, who had invalid social security numbers (or Ontario health card numbers), who were transferred into a care center from another acute care institution, who had been hospitalized with an AMI in the previous year, or had left bundle-branch block on ECG.
We only included patients who had a confirmed AMI defined as either (1) creatine kinase-MB fraction Ͼ0.05, (2) elevation of troponin I or T above the upper limit of normal at a given hospital, or (3) 2 of the following: presence of chest pain, a 2-fold elevation of creatine kinase, or ST-segment elevation on ECG.
Census Regions
We divided the US cohort into 4 census regions (northeastern, southern, midwestern, and western United States) based on the state in which the patients were hospitalized. 22 These regions were chosen a priori such that the sample sizes of AMI patients in each region would be comparable to the Ontario cohort.
Process of Care and Mortality
Patients were identified as eligible for discharge medications if they had survived to hospital discharge and were not transferred out to another acute care hospital. We identified ideal candidates for aspirin, ␤-blockers, and angiotensin-converting enzyme inhibitors at discharge by exclusion of eligible patients who had contraindications to therapy. We harmonized the definition of "ideal" so that data elements common to both databases could be used in an identical fashion. 19, 23 We assessed mortality after hospital admission by linking the clinical data sets to the Medicare enrollment database and billing records in the United States, and the Ontario Registered Persons Database in Canada, which contains information on the vital status of all Ontario residents. 24, 25 Risk-standardized mortality rates at 30 days were chosen as our primary mortality outcome and riskstandardized mortality rates at 1 year and 3 years were chosen as secondary outcomes.
Statistical Analysis
Because of national privacy laws that restrict the combination of individual patient information, analyses of US and Canadian data were performed separately. We compared demographics, clinical characteristics, and therapies between the entire US and Ontario cohorts. We also compared these characteristics across geographic regions with 2 tests for categorical variables and F tests with 4 degrees of freedom for continuous variables. We considered probability values of Ͻ0.001 as statistically significant in order to reduce type I error due to multiple comparisons performed in the present study. We acknowledge that because of the large number of patients in our cohorts, it is possible that small differences may be detected as statistically significant, and we therefore carefully considered clinically important results. We also examined the relationship between regional cardiac catheterization rates and availability of cardiac facilities by linear regression. An R 2 statistic was calculated to assess the strength of association and Studentized residuals were used to assess potential outliers.
To account for differences in baseline risk in comparisons of mortality rates, we first calculated mortality risk scores for each national cohort from the in-hospital prediction risk score from the Global Registry of Acute Coronary Events (GRACE) study. 26 We then calculated direct standardized mortality rates of patients hospitalized in the United States (or different regions in the United States) from the risk score distribution in the Canadian cohort as the standard. This method allowed estimation of mortality rates that would be expected in the US cohort if it were to have the same risk distribution as the Canadian cohort, which thus enabled us to adjust for differences in baseline risk without combining our data sets.
Statistical analyses were conducted with SAS version 9.1 software (SAS Institute Inc, Cary, NC), and direct standardized mortality calculation was performed with STATA statistical software (Version 8.0; STATA Corp, College Station, TX).
The authors had full access to the data and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
The US study cohort included 38 886 patients and the Canadian cohort included 5634 patients who were hospital-ized in Ontario after inclusion and exclusion criteria were applied (Table 1) . Table 2 provides the clinical, physician, and hospital characteristics of AMI patients treated in each region. Mean age of hospitalized AMI patients ranged from 76.9 years in Ontario to 78.7 years in the northeastern United States. Although many admission characteristics of AMI patients were not substantially different across all regions, Ontario patients had the lowest rates of hypertension, diabetes, prior myocardial infarction, and prior coronary interventions (Table 2) . Mean GRACE risk scores of AMI patients also did not differ significantly across the US regions and Ontario ( Table 2) . AMI patients in the northeastern United States and Ontario were the most likely to have been admitted to hospitals without cardiac-invasive facilities compared with other US regions ( Table 2 ).
Clinical, Physician, and Hospital Characteristics
Regional Variations in Medical Therapy and Cardiac Procedure Use
Among ideal candidates, ␤-blocker use was highest in the northeastern United States, angiotensin-converting enzyme inhibitor use was highest in Ontario, and early reperfusion therapy use was highest in the western United States (Table  3 ). Cardiac catheterization rates were significantly higher in the United States compared with Ontario (Table 3) . We observed substantial regional differences in cardiac catheterization use in the United States, however. When cardiac catheterization rates in each US region were compared with rates in Ontario, the rates in the northeastern United States were more similar to Ontario than other regions of the United States. Similar utilization patterns of percutaneous coronary intervention and coronary artery bypass surgery were observed, with the northeastern United States being more similar to Ontario than other regions of the United States (Table 3 ). On the other hand, physicians in the northeastern United States and Ontario were more likely to evaluate ischemia noninvasively after AMI and had the highest utilization rates of stress tests during hospitalization (Table 3) . Table 4 shows the demographic and admission characteristics of AMI patients who received cardiac catheterization during hospitalization. AMI patients hospitalized in different regions had similar age, clinical characteristics, and mean GRACE risk score. In addition, patients who received cardiac catheterization in the northeastern United States and Ontario, areas of lower utilization of cardiac catheterization, had similar demographic and admission characteristics compared with other regions with higher utilization rates.
There was a strong association between the use of cardiac catheterization and the availability of cardiac-invasive facilities (R 2 ϭ0.81) ( Figure 1 ). Observed rates of cardiac catheterization were below the best-fit line of expected rates in the northeastern United States and higher than expected in the western United States. None of the regions were considered outliers as all regions had Studentized residuals within the expected range of Ϫ2 to 2.
Mortality Outcomes
The area under the receiver-operating characteristic curve of the GRACE mortality model was 0.76 for the US cohort and 0.80 for the Canadian cohort, which indicated good discriminative ability of the GRACE risk score within each cohort. Risk-standardized mortality rates at 30 
Discussion
To the best of our knowledge, the present study is the first United States-Canada comparison study that uses clinical data from population-representative samples to compare AMI treatment patterns and outcomes. Although we observed significantly higher overall utilization rates of cardiac invasive procedures in the United States compared with Canada, these differences varied substantially according to geographic regions in the United States. In fact, AMI treatment patterns were quite similar in the northeastern United States and Ontario, as both regions had relatively low rates of cardiacinvasive procedures but among the highest rates of medication use compared with other US regions. Less intensive use of cardiac-invasive procedures in the northeastern United States and Ontario was not associated with poorer outcomes in the short and longer term after hospitalization compared with other US regions. This observation may imply that regions can deliver quality of care to AMI patients with similar mortality outcomes at lower cost. Our findings also suggest that, in addition to rules and regulations in each country, local regional practice patterns may also substantially influence treatment patterns. Future United States-Canada comparisons should perhaps include regional analyses, as it is possible that simple national comparisons may obscure important differences that exist between regions.
Cardiac-invasive procedures are highly dependent on the availability of resources. 16, [27] [28] [29] It is therefore not surprising to observe that lower utilization rates in the northeastern United States and Ontario were associated with a lower supply of cardiac-invasive facilities. It is well known that Canadian federal budget deficits during the 1990s created a strain on specialized services. 3 Although Ontario continues to have the lowest utilization of cardiac catheterization, our observed rate of 16.8% during hospitalization is actually Ͼ2-fold higher than the rate of 6.3% at 30 days observed in 1991 to 1992. 4 It has also been suggested that Canadian patients do not receive timely access to quality care. 30, 31 Our observation that Ontario had the fewest number of catheterization facilities that treat patients with similar illness severity lends support to recent initiatives to improve timely access and quality health care for Canadians. 32 Because the northeastern United States does not face similar resource constraints compared to Ontario, it is more difficult to understand why the northeastern United States consistently performed fewer cardiac invasive procedures, had a smaller number of invasive facilities, and performed lower proportion of cardiac invasive procedures per facility than other US regions. 16, 29 We observed that patients who underwent cardiac catheterization had admission characteristics and similar GRACE risk scores, which indicated that illness severity was unlikely a major reason to explain variations in invasive procedures. Other possible reasons to explain procedural variations that we were unable to explore include differences in physician attitudes toward invasive treatment, patient preferences, and unmeasured regional characteristics. 13, 16 Although we cannot determine the optimal rate of cardiac catheterization after AMI, the less aggressive invasive approach observed in the northeastern United States and Ontario was not associated with worse short-or long-term survival after adjustment for patient and hospital factors. Findings from our study mirror those of other populationbased studies, where increased invasive procedure utilization had no significant impact on mortality after AMI. 4, 13, 29, 33 Several reasons may explain why benefits shown in randomized trials do not translate to the population level. First, evidence has suggested that there may only be marginal additional benefits of coronary interventions in patients who already receive optimal medical therapy. 29 Second, the impact of any evidence-based cardiovascular therapy in the population is predominantly dependent on a patient's baseline risk of future cardiovascular events (ie, greater benefits in higher-risk patients); 34 a "paradox" has been observed, however, in which aggressive medical and interventional therapies are often applied to patients at relatively low risk of adverse outcomes. 35, 36 Finally, data suggest that invasive therapies need to be used in a timely fashion to optimize their benefits. 37, 38 Therefore, delays in the use of invasive therapies may have diminished the potential benefits of cardiac invasive procedures in clinical practice. 39 We chose risk-standardized mortality at 30 days as our primary outcome of interest because it is likely most reflective of in-hospital processes of care. Risk-standardized mortality rates were similar between the United States and Ontario at 30 days. However, we found that longer-term mortality at 1 year and at 3 years were lower in Ontario in secondary analyses. A phenomenon of better short-term survival rates in the United States followed by better intermediate-term survival rates in Canada has also been previously observed in other studies. 4, 40 We could not assess the possible reasons for this finding in our study, but a recent study that surveyed both countries found that US residents had more chronic conditions but were less likely to have a regular physician, more likely to have unmet health needs, and more likely to forgo needed medications because of coast. 41 It is also possible that long-term survival after an AMI is more dependent on the general health status of patients and/or the quality of outpatient care (eg, primary care, medication adherence) than on the quality of in-hospital care. Further research studies are needed to identify the reasons for the important long-term outcome differences observed in this study.
Although the use of evidence-based medical therapies varied significantly less across regions, we still observed a 12% absolute difference for ␤-blockers and 6% for angiotensin-converting enzyme inhibitors among the highest to lowest utilization regions among ideal candidates. There are no obvious reasons to explain why regional variations in medical treatment exist, as published evidence that demonstrates its effectiveness is widely available and evidence-based thera-pies can be prescribed at a low cost. Previous data suggest that regional differences in the use of medical therapy persist even after adjustment for other patient, physician, and hospital characteristics. 13 Understanding of the possible factors that underlie these regional variations will be crucial to ongoing improvements to the care and outcomes of patients with AMI.
Several limitations of our study merit consideration. First, privacy laws in the United States and Canada restricted transfer of patient level data outside each country and prevented the combination of data sets. However, both data sets contained detailed information on demographics, admission characteristics, medication use, and invasive procedures that provided comprehensive insights into regional variations in processes of care. We did not examine regional practice variations in Canada because similar clinically abstracted data sets were not available from other provinces. However, it has been demonstrated that population utilization rates of cardiac catheterization in Ontario (509.6 per 100 000 population) are highly representative of the overall rates in Canada (471.5 per 100 000). 41 Third, although we did not have information on outpatient use of medication after AMI discharge, prescription at hospital discharge is one of the strongest predictors of long-term use. [42] [43] [44] Fourth, the US cohort was a random sample of an equal number of AMI patients hospitalized in each state and the Ontario cohort was a random sample of AMI patients representative of the entire province. However, we performed additional analyses by weighting the US sample based on the population in each state and found similar mortality results. Finally, we were unable to compare other nonfatal outcomes after AMI such as quality of life, left ventricular ejection fraction, or heart failure hospitalization because these data were not available.
In conclusion, despite marked differences between the American and the Canadian health care systems, the similarity of AMI treatment between the northeastern United States and Ontario suggests that local regional practice patterns play a substantial role in the influence of the delivery of care. Further exploration of factors that underlie these regional variations may provide insights to improve the quality of care for patients with AMI.
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